Replimune Group, Inc.
RP1
advanced melanoma
Countdown
25days
Advisory committee · ~ Jul 31, 2026 estimated
What's at stake
An FDA advisory committee reviews RP1 for advanced melanoma around ~ Jul 31, 2026. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 13h ago
“has notified the company to expect an advisory committee meeting in late July.”